

# NIH Public Access

**Author Manuscript** 

J Am Chem Soc. Author manuscript; available in PMC 2011 September 8.

Published in final edited form as:

JAm Chem Soc. 2010 September 8; 132(35): 12216–12217. doi:10.1021/ja105772z.

Highly Enantioselective Catalytic Dynamic Resolution of *N*-Boc-2-lithiopiperidine: Synthesis of (*R*)-(+)-*N*-Boc-Pipecolic Acid, (*S*)-(-)-Coniine, (*S*)-(+)-Pelletierine, (+)- $\beta$ -Conhydrine, (*S*)-(-)-Ropivacaine, and Formal Synthesis of (-)-Lasubine II and (+)-Cermizine C

## Timothy K. Beng and Robert E. Gawley

Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR, 72701, USA

# Abstract



The catalytic dynamic resolution (CDR) of *rac*-2-lithio-*N*-Boc-piperidine using chiral ligand **8** or its diastereomer **9**, in the presence of TMEDA has led to the highly enantioselective syntheses of either enantiomer of 2-substituted piperidines using a wide range of electrophiles. The CDR has been applied to the synthesis of *R*- or *S*-pipecolic acid derivatives, (+)- $\beta$ -conhydrine, (*S*)-(+)-pelletierine, (*S*)-(-)-ropivacaine, and formal synthesis of (-)-lasubine II and (+)-cermizine C.

2-Substituted piperidines are found in many alkaloids and medicinal compounds which are derived from pipecolic acid. In 1989, Beak showed that racemic members of this class of compounds can be conveniently prepared by deprotonation and electrophilic quench of *N*-Boc-piperidine, **1**, using *s*-BuLi and *N*, *N*, *N'*, *N'*-tetramethylethylenediamine (TMEDA).1 Although the chiral base *s*-BuLi/(–)-sparteine efficiently and enantioselectively deprotonates *N*-Boc-pyrrolidine,2 the same base complex is less effective with *N*-Boc-piperidine.3 Partial success has recently been reported using O'Brien's (+)-sparteine surrogate, which affords up to 88:12 er (*R*:*S*) in variable yields (depending on the electrophile), but this method is limited to one enantiomer.4

An alternative approach is the use of dynamic resolutions, and the most successful results to date for resolution of 2-lithio piperidines have been reported by the Coldham group.5 In dynamic thermodynamic resolutions (DTRs), chiral ligands coordinate to the metal of a chiral organolithium causing it to undergo carbanion inversion at a selected temperature, and populate one stereoisomer through equilibration. Upon cooling to freeze the equilibrium, reaction with an electrophile gives enantioenriched products.6 Coldham recently reported

bgawley@uark.edu.

Supporting Information Available: Full experimental details and spectroscopic data. This information is available free of charge via the internet at http://pubs.acs.org

that *N*-Boc-2-lithiopiperidine **2** can be resolved by DTR using several monolithiated diamino alkoxide ligands (Scheme 1).5

A catalytic dynamic resolution (CDR) of 2-lithio-*N*-trimethylallylpyrrolidine was recently reported.7 We now report the discovery of a CDR of *rac*-**2** using new ligands that afford excellent enantioselectivity, *for either enantiomer of 2-substituted piperidines*.

In their report on the stoichiometric DTR of *rac-2*, Coldham, et al, indicated that the resolution is facilitated by the addition of lithium isopropoxide.5 With this in mind, we investigated the enantioselectivity of dilithio diaminoalkoxides **7–9** in a stoichiometric DTR using the Coldham conditions. We were gratified to find the high er's shown in Figure 1. Note that diastereometric ligands **8** and **9** afford very high er, and *opposite* configurations of **3**.

A successful CDR depends on several factors, including a lower barrier for DTR than for racemization at a given temperature.8 A plot of  $\Delta G^{\ddagger}$  vs. temperature for racemization of **2** in the presence of TMEDA and DTR of **2**·8 in the presence of TMEDA revealed that the barrier for DTR is lower than for racemization below -27 °C (see Supporting Information). Thus a CDR was attempted by generating the racemic organolithium 2 by deprotonation in Et<sub>2</sub>O at -78 °C with *s*-BuLi/TMEDA, followed by addition of 10 mol% of 8, warming to -45 °C for three hours, then cooling to -78 °C and quenching with Me<sub>3</sub>SiCl. We were gratified to obtain **3** in 74% yield and 96:4 er (Table 1, entry 1). Several other electrophiles were evaluated under the same CDR conditions, with the results summarized in Table 1, entries 2–14. Excellent enantiomer ratios and good yields were obtained in all cases. Procedures to recover the chiral ligand are included in the SI.

CDR using ligand **8** and quenching with Bu<sub>3</sub>SnCl afforded (*S*)-**10** in 66% yield and 96:4 er. With ligand **9**, (*R*)-**10** was obtained in 62% yield and 97:3 er. When CO<sub>2</sub> was used as electrophile, *N*-Boc-(*R*)-(+)-pipecolic acid, (*R*)-**11**, was obtained in 78% yield and 98:2 er using 8. Quenching with ClCO<sub>2</sub>Me afforded enantiopure methyl pipecolate ester (*R*)-**12** using ligand **8** and (*S*)-**12** using ligand **9**. Reaction with PhNCO afforded enantiopure anilide (*R*)-**13** using ligand **8**.

The electrophilic bimolecular substitutions discussed above (entries 1 to 7), proceed *via* a polar pathway, presumably with retentive substitution at the metal bearing carbon ( $S_E$ 2ret).9 However, when (*S*)-2 was trapped directly with either allyl chloride or benzyl bromide, nearly racemic products were obtained. These nonselective reactions probably proceed through a single electron transfer (SET) pathway.10 The enantioselectivity of the allylations was therefore evaluated under Negishi conditions, which have been successfully applied in this system,4 whereby 2 is transmetalated with ZnCl<sub>2</sub> and coupled using CuCN·2LiCl. Under these conditions, allyl bromide afforded (*R*)-14 with ligand 8 in 63% yield and 95:5 er (entry 8). When CDR using ligand 9 was employed, (*S*)-14 was obtained in 59% yield and 96:4 er (entry 9). A similar protocol using ligand 8 and Negishi coupling with benzyl bromide gave enantiopure (*R*)-15 in 65% yield (entry 10).

CDR of *rac-2*, followed by addition to aldehydes and ketones was also investigated, with the results summarized in Table 1, entries 11-14. Not surprisingly,11 the adducts from addition to cyclohexanone, benzaldehyde, and 1-naphthaldehyde cyclized, *in situ*, to oxazolidinones, the latter two as mixtures of diastereomers. Nevertheless, the configuration at the lithiumbearing carbon of **2** was maintained, with all adducts exhibiting high er's. Quenching with acetaldehyde provides a convenient way to prepare the enantiopure alcohol **19** in 78% yield as a mixture of diastereomers (85:15 dr, entry 14).

When (*S*)-**2** was quenched with propionaldehyde, the alcohol **20** was obtained as a 70:30 mixture of diastereomers, both of which had 96:4 er. Separation of the diastereomers by column chromatography and hydrolysis of the carbamate from the major diastereomer afforded the alkaloid (+)- $\beta$ -conhydrine (Scheme 2).

Hydrogenation of (*S*)-14 and deprotection afforded (*S*)-(-)-coniine; Wacker oxidation and deprotection afforded (*S*)-(+)-pelletierine (Scheme 3). Cheng and coworkers have recently prepared (*S*)-14 from glutaraldehyde in 6 steps, and showed that (*S*)-14 can be readily converted to (-)-lasubine II and (+)-cermizine C via (*S*)-(+)-pelletierine.12

CDR of **2** with ligand **9** and electrophilic quench with 2,6-dimethylphenyl isocyanate afforded enantiopure (>99:1 er) (*S*)-**21** in 69% yield (Scheme 4). After deprotection, alkylation with 1-bromopropane in the presence of  $K_2CO_3$  yielded (*S*)-(–)-ropivacaine in three overall steps and 61% overall yield.

In summary, the discoveries of ligands **8** and **9** coupled with their ability to resolve *N*-Boc-2-lithiopiperidine catalytically have provided an efficient route for the highly enantioselective syntheses of 2-substituted piperidines of either absolute configuration.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was supported by the Arkansas Biosciences Institute and the National Science Foundation (CHE 0616352 and 1011788). Core facilities were funded by the National Institutes of Health (R15569) and the Arkansas Biosciences Institute. The authors are grateful to Professors Dieter Seebach and Iain Coldham for helpful discussions.

## References

- 1. Beak P, Lee WK. Tetrahedron Lett. 1989; 30:1197.
- 2. Kerrick ST, Beak P. J Am Chem Soc. 1991; 113:9708.
- 3. Bailey WF, Beak P, Kerrick ST, Ma S, Wiberg KB. J Am Chem Soc. 2002; 124:1889. [PubMed: 11866600]
- Stead D, Carbone G, O'Brien P, Campos KR, Coldham I, Sanderson A. J Am Chem Soc. 2010; 132:7260. [PubMed: 20462193]
- 5. Coldham I, Raimbault S, Chovatia PT, Patel JJ, Leonori D, Sheikh NS, Whittaker DTE. Chem Commun. 2008:4174.
- 6. (a) Lee WK, Park YS, Beak P. Acc Chem Res. 2009; 42:224. [PubMed: 19152329] (b) Coldham, I.; Sheikh, NS. Topics in Stereochemistry. Gawley, RE., editor. Vol. 26. VHCA; Zürich: 2010. p. 253
- 7. Beng TK, Yousaf TI, Coldham I, Gawley RE. J Am Chem Soc. 2009; 131:6908. [PubMed: 19405472]
- 8. A mechanistic study of the DTR and CDR of rac-2 will be published elsewhere.
- 9. Gawley RE. Tetrahedron Lett. 1999; 40:4297.
- 10. (a) Rein KS, Chen ZH, Perumal PT, Echegoyen L, Gawley RE. Tetrahedron Lett. 1991; 32:1941.
  (b) Gawley RE, Low E, Zhang Q, Harris R. J Am Chem Soc. 2000; 122:3344. (c) Gawley RE, Eddings DB, Santiago M. Org Biomol Chem. 2006; 4:4285. [PubMed: 17102873]
- 11. Beak P, Lee WK. J Org Chem. 1993; 58:1109.
- 12. Cheng G, Wang X, Su D, Liu H, Liu F, Hu Y. J Org Chem. 2010; 75:1911. [PubMed: 20155953]







Scheme 1. DTR of *N*-Boc-2-lithiopiperidine 2.5

![](_page_5_Figure_2.jpeg)

#### Scheme 2.

Synthesis of (+)- $\beta$ -conhydrine

i) s-BuLi (1.2 equiv), Et2O, TMEDA (4.0 equiv), -78 °C, 3 h; ii) 8, (10 mol%), -45 °C, 3 h; iii) EtCHO, -78 °C, 2 h; iv) CF3CO2H, CH2Cl2.

![](_page_6_Figure_2.jpeg)

#### Scheme 3.

Synthesis of (*S*)-(+)-pelletierine and (*S*)-(-)-coniine. Formal synthesis of (-)-lasubine II and (+)-cermizine C.12

i)  $Pd(OH)_2$  (1.0 eq),  $H_2$  (1 atm), MeOH, rt, 48 h; ii)  $CF_3CO_2H$ ,  $CH_2Cl_2$ , 0 °C, 2 h, then NaOH, pH 10; iii)  $PdCl_2$  (1.0 eq), CuCl (10 mol%),  $O_2$ , DMF/H<sub>2</sub>O (10:1), rt, 10 h; iv)  $CF_3CO_2H$ ,  $CH_2Cl_2$ , 0 °C, 2 h, then NaOH.

$$\begin{array}{c} \bigcap_{\substack{N \\ Boc}} \stackrel{i}{\longrightarrow} \left( \begin{array}{c} N \\ N \\ R \end{array} \right) \stackrel{H}{\longrightarrow} \left( \begin{array}{c} H \\ S21; R = Boc \\ S22; R = H \end{array} \right) ii, 100\% \quad S^{(-)-ropivacaine} \end{array}$$

#### Scheme 4.

Synthesis of (S)-(-)-Ropivacaine

i) *s*-BuLi (1.2 eq), Et<sub>2</sub>O, TMEDA (4.0 eq), -78 °C, 3 h, then **9**, (10 mol%), -45 °C, 3 h, -78 °C, 2,6-dimethylphenyl isocyanate, 2 h, >99:1 er; ii) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 10 h, then NaOH; iii) isopropyl alcohol, 1-bromopropane (3.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), H<sub>2</sub>O, 100 °C, 6 h.

## Table 1

CDR of 2 at -45 °C for 3 h using ligand 8 (or 9 where noted).

		$ \begin{array}{c c} & 1. \ s{-}BuLi, 4 \ eq \ TMEDA, -78 \ ^{\circ}C \\ 2. \ 10 \ mol \ ^{\circ}L^{\ast}, \ -45 \ ^{\circ}C \\ Boc \\ 1 \end{array} \begin{array}{c} & N \\ Boc \\ 1 \end{array} \begin{array}{c} & N \\ Boc \\ Et_2O \\ L^{\ast} = 8 \end{array} \begin{array}{c} & N \\ Boc \\ L^{\ast} = 9 \end{array} \begin{array}{c} & O \\ & O \\ Boc \\ L^{\ast} = 9 \end{array} $		
Entry	$\mathbf{E}^+$	Product(s)	% Yield	er
1	Me <sub>3</sub> SiCl	(S)- <b>3</b>	74	96:4
2	Bu <sub>3</sub> SnCl	(S)- <b>10</b>	66	96:4
3	Bu <sub>3</sub> SnCl	( <i>R</i> )-10	62	97:3 <sup>a</sup>
4	CO <sub>2</sub>	( <i>R</i> )-11	78	98:2
5	MeOCOC1	( <i>R</i> )-12	88	>99:1
6	MeOCOCl	(S)- <b>12</b>	85	>99:1 <sup>a</sup>
7	PhNCO	( <i>R</i> )-13	68	>99:1
8	Allyl bromide	( <i>R</i> )- <b>14</b>	63	95:5 <sup>b</sup>
9	Allyl bromide	( <i>S</i> )-14	59	96:4 <sup><i>a</i>,<i>b</i></sup>
10	BnBr	( <i>R</i> )-15	65	>99:1 <sup>b</sup>
11	Cyclohexanone		60	94:6

![](_page_9_Figure_2.jpeg)

<sup>a</sup>Using ligand **9** 

<sup>b</sup>via Negishi cross coupling

<sup>c</sup>Major diastereomer illustrated